Eisai CEO Naito

Eisai CEO Naito

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., speaks during a press conference in Tokyo on July 7, 2023, after the U.S. Food and Drug Administration granted full approval for Eisai and Biogen Inc.'s anti-Alzheimer's drug lecanemab.

Eisai CEO Naito

Eisai CEO Naito

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., speaks during a press conference in Tokyo on July 7, 2023, after the U.S. Food and Drug Administration granted full approval for Eisai and Biogen Inc.'s anti-Alzheimer's drug lecanemab.

Eisai CEO Naito

Eisai CEO Naito

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., speaks during a press conference in Tokyo on July 7, 2023, after the U.S. Food and Drug Administration granted full approval for Eisai and Biogen Inc.'s anti-Alzheimer's drug lecanemab.

Eisai CEO Naito

Eisai CEO Naito

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., speaks during a press conference in Tokyo on July 7, 2023, after the U.S. Food and Drug Administration granted full approval for Eisai and Biogen Inc.'s anti-Alzheimer's drug lecanemab.

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.

Fujifilm to buy Biogen unit

Fujifilm to buy Biogen unit

Fujifilm Holdings Corp. President Shigetaka Komori meets the press in Tokyo on March 12, 2019, over the company's plan to buy a unit of U.S. drugmaker Biogen Inc. (Kyodo) ==Kyodo